Huahai Pharma gains approval for two new drugs

Zhejiang Huahai Pharmaceutical (SSE:600521) announced it has received drug registration certificates from the National Medical Products Administration for Mesocarbamol Injection and Posaconazole Enteric-coated Tablets. The Mesocarbamol Injection, indicated for acute musculoskeletal pain, saw a CN￥4.68 million investment in R&D and projects a CN￥206 million market in the first half of 2024. The Posaconazole Enteric-coated Tablets, used to treat and prevent invasive fungal infections, required a CN￥1,202 million investment and are projected to have a CN￥240 million market in the first half of 2024. The approvals are expected to enhance the company's market competitiveness.